Literature DB >> 435708

Therapeutic effect of cimetidine in patients undergoing haemodialysis.

R H Jones, M R Lewin, V Parsons.   

Abstract

Blood concentrations of cimetidine were measured and the therapeutic effect of the drug assessed patients undergoing maintenance haemodialysis. Thirteen patients were given a single oral 200-mg dose of cimetidine a mean of 2.7 hours before the start of dialysis. Dialysing for 6--12-6 m2 hours led to a mean fall of 71% in blood cimetidine concentration during haemodialysis. Nine patients with various upper gastrointestinal lesions diagnosed endoscopically were treated for up to six weeks with a reduced cimetidine dose of 200 mg 12-hourly; two patients received two courses of treatment. Repeat endoscopy after treatment disclosed satisfactory healing, and the drug did not accumulate. This lower dose regimen is recommended for patients receiving dialysis who develop upper gastrointestinal lesions for which a histamine H2-receptor antagonist is indicated.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 435708      PMCID: PMC1598296          DOI: 10.1136/bmj.1.6164.650

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  22 in total

1.  Pharmacological evaluation of cimetidine, a new histamine H2-receptor antagonist, in healthy man.

Authors:  W L Burland; W A Duncan; T Hesselbo; J G Mills; P C Sharpe; S J Haggie; J H Wyllie
Journal:  Br J Clin Pharmacol       Date:  1975-12       Impact factor: 4.335

2.  Reactions to cimetidine.

Authors:  T A Grimson
Journal:  Lancet       Date:  1977-04-16       Impact factor: 79.321

3.  Peptic ulceration, gastric secretion, and renal transplantation.

Authors:  G D Chisholm; A D Mee; G Williams; J E Castro; J H Baron
Journal:  Br Med J       Date:  1977-06-25

4.  Hypergastrinaemia in chronic renal failure.

Authors:  M G Korman; M C Laver; J Hansky
Journal:  Br Med J       Date:  1972-01-22

5.  Cimetidine for duodenal ulceration in patients undergoing haemodialysis.

Authors:  C C Doherty; F A O'Connor; K D Buchanan; M G McGeown
Journal:  Br Med J       Date:  1977-12-10

6.  Cimetidine in patients with gastric ulcer: a multicentre controlled trial.

Authors:  F Frost; I Rahbek; S J Rune; K B Jensen; E Gudmand-Hoyer; E Krag; J Rask-Madsen; H R Wulff; J Garbol; K G Jensen; M Hojlund; V R Nissen
Journal:  Br Med J       Date:  1977-09-24

7.  H2-receptor antagonists and antacids in the prevention of acute gastrointestinal haemorrhage in fulminant hepatic failure. Two controlled trials.

Authors:  B R Macdougall; R J Bailey; R Williams
Journal:  Lancet       Date:  1977-03-19       Impact factor: 79.321

8.  Oral cimetidine in severe duodenal ulceration. A double-blind controlled trial.

Authors:  G R Gray; I S Smith; I McKenzie; G P Crean; G Gillespie
Journal:  Lancet       Date:  1977-01-01       Impact factor: 79.321

9.  Cimetidine in the treatment of active duodenal and prepyloric ulcers.

Authors:  G Bodemar; A Walan
Journal:  Lancet       Date:  1976-07-24       Impact factor: 79.321

10.  Gastric and duodenal ulcer and their associated diseases.

Authors:  M J Langman; A R Cooke
Journal:  Lancet       Date:  1976-03-27       Impact factor: 79.321

View more
  9 in total

1.  Pharmacokinetics and dynamics of famotidine in patients with renal failure.

Authors:  U Gladziwa; U Klotz; D R Krishna; H Schmitt; W M Glöckner; H Mann
Journal:  Br J Clin Pharmacol       Date:  1988-09       Impact factor: 4.335

2.  Prophylactic gastric operations in uremic patients prior to renal transplantation. Invited commentary.

Authors:  A Flatmark
Journal:  World J Surg       Date:  1979-08-31       Impact factor: 3.352

3.  Pharmacokinetics of famotidine, a new H2-receptor antagonist, in relation to renal function.

Authors:  T Takabatake; H Ohta; M Maekawa; Y Yamamoto; Y Ishida; H Hara; S Nakamura; Y Ushiogi; M Kawabata; N Hashimoto
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

Review 4.  Pharmacokinetics and pharmacodynamics of H2-receptor antagonists in patients with renal insufficiency.

Authors:  U Gladziwa; U Klotz
Journal:  Clin Pharmacokinet       Date:  1993-04       Impact factor: 6.447

Review 5.  Clinical pharmacokinetics of cimetidine.

Authors:  A Somogyi; R Gugler
Journal:  Clin Pharmacokinet       Date:  1983 Nov-Dec       Impact factor: 6.447

6.  Pharmacokinetics of cimetidine and its sulphoxide metabolite during haemodialysis.

Authors:  R Larsson; P Erlanson; G Bodemar; B Norlander; L Fransson; L Strouth
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

7.  The pharmacokinetics of cimetidine and its sulphoxide metabolite in patients with normal and impaired renal function.

Authors:  R Larsson; P Erlanson; G Bodemar; A Walan; A Bertler; L Fransson; B Norlander
Journal:  Br J Clin Pharmacol       Date:  1982-02       Impact factor: 4.335

Review 8.  Pharmacokinetic optimisation of the treatment of peptic ulcer in patients with renal failure.

Authors:  U Gladziwa; U Koltz
Journal:  Clin Pharmacokinet       Date:  1994-11       Impact factor: 6.447

9.  Effects of age and chronic renal failure on the urinary excretion kinetics of famotidine in man.

Authors:  J H Lin; A N Chremos; K C Yeh; J Antonello; G A Hessey
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.